Patient satisfaction and sensory attributes of Mometasone Furoate delivered by a novel nasal spray device: an observational, real-world study

<bold>Background:</bold> Intranasal corticosteroids for treating nasal inflammation are frequently administered by nasal spray delivery devices consisting of a chamber, a piston and an operating actuator. <bold>Aims:</bold> To investigate patients’ satisfaction with, and importance of treatment attributes of Mometasone Furoate delivered by the nasal spray VP393F device using an Anchored Best-Worst Scaling (ABWS) method. <bold>Methods:</bold> Adult patients with postnasal drip due to allergic rhinitis were switched from conventional nasal sprays to the VP393F nasal device delivering Mometasone Furoate (Bruschettini srl, Italy). Before and two weeks after switching, patients completed a questionnaire incorporating an ABWS with 11 domains: 7 sensory (immediate and after taste of medication, smell of medication, nose irritation, urge to sneeze, dripping out your nose/down your throat, dryness of your nose/ throat) and 4 treatment-related (convenience, fast acting, duration of effect, and symptom control). The ABWS involved rescaling individual BWS scores using anchored ratings (0–10) for most and least satisfied/important domains to create a 0-100 total satisfaction index (TSI). <bold>Results:</bold> After switching, ten patients (8 females, aged 56±8 yr) had similar TSI but higher (P<0.05) satisfaction in 2 (convenience and fast acting) of 11 domains and regarded 3 (dripping out your nose/down your throat, dryness of your nose or throat, duration of effect) of 11 domains as more important (P<0.05) compared to the previous devices. <bold>Conclusion:</bold> Patients using the VP393F nasal device were satisfied compared to previous nasal delivery systems, especially regarding sensory attributes.